- Home
- NTLA
as of 03-16-2026 3:59pm EST
Intellia Therapeutics is a gene-editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.
| Founded: | 2014 | Country: | United States |
| Employees: | N/A | City: | CAMBRIDGE |
| Market Cap: | 1.5B | IPO Year: | 2016 |
| Target Price: | $20.45 | AVG Volume (30 days): | 3.6M |
| Analyst Decision: | Buy | Number of Analysts: | 20 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.81 | EPS Growth: | 27.43 |
| 52 Week Low/High: | $5.90 - $28.24 | Next Earning Date: | 05-21-2026 |
| Revenue: | $67,671,000 | Revenue Growth: | 16.92% |
| Revenue Growth (this year): | -10.98% | Revenue Growth (next year): | 73.07% |
| P/E Ratio: | -3.35 | Index: | N/A |
| Free Cash Flow: | -395865000.0 | FCF Growth: | N/A |
AI-Powered NTLA Daily Prediction
Machine learning model trained on 25+ technical indicators
AI Recommendation
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Intellia Therapeutics Inc. (NTLA)
EVP, General Counsel
Avg Cost/Share
$13.78
Shares
1,211
Total Value
$16,687.58
Owned After
156,794
SEC Form 4
EVP, Chief Technical Officer
Avg Cost/Share
$13.78
Shares
607
Total Value
$8,364.46
Owned After
93,864
SEC Form 4
Director
Avg Cost/Share
$9.35
Shares
150,000
Total Value
$1,402,500.00
Owned After
207,453
SEC Form 4
EVP, Chief Financial Officer
Avg Cost/Share
$9.21
Shares
6,379
Total Value
$58,750.59
Owned After
99,683
SEC Form 4
EVP, General Counsel
Avg Cost/Share
$9.21
Shares
10,397
Total Value
$95,756.37
Owned After
156,794
SEC Form 4
President and CEO
Avg Cost/Share
$9.21
Shares
34,146
Total Value
$314,484.66
Owned After
1,013,339
SEC Form 4
EVP, Chief Medical Officer
Avg Cost/Share
$9.21
Shares
11,903
Total Value
$109,626.63
Owned After
121,249
SEC Form 4
EVP, Chief Technical Officer
Avg Cost/Share
$9.21
Shares
9,515
Total Value
$87,633.15
Owned After
93,864
SEC Form 4
VP, Chief Accounting Officer
Avg Cost/Share
$9.21
Shares
2,989
Total Value
$27,528.69
Owned After
52,277
SEC Form 4
EVP, Chief Scientific Officer
Avg Cost/Share
$9.21
Shares
8,508
Total Value
$78,358.68
Owned After
98,533
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| BASTA JAMES | NTLA | EVP, General Counsel | Mar 2, 2026 | Sell | $13.78 | 1,211 | $16,687.58 | 156,794 | |
| Clark Eliana | NTLA | EVP, Chief Technical Officer | Mar 2, 2026 | Sell | $13.78 | 607 | $8,364.46 | 93,864 | |
| Cohen Fred E | NTLA | Director | Jan 5, 2026 | Buy | $9.35 | 150,000 | $1,402,500.00 | 207,453 | |
| Dulac Edward J III | NTLA | EVP, Chief Financial Officer | Jan 5, 2026 | Sell | $9.21 | 6,379 | $58,750.59 | 99,683 | |
| BASTA JAMES | NTLA | EVP, General Counsel | Jan 5, 2026 | Sell | $9.21 | 10,397 | $95,756.37 | 156,794 | |
| LEONARD JOHN M | NTLA | President and CEO | Jan 5, 2026 | Sell | $9.21 | 34,146 | $314,484.66 | 1,013,339 | |
| Lebwohl David | NTLA | EVP, Chief Medical Officer | Jan 5, 2026 | Sell | $9.21 | 11,903 | $109,626.63 | 121,249 | |
| Clark Eliana | NTLA | EVP, Chief Technical Officer | Jan 5, 2026 | Sell | $9.21 | 9,515 | $87,633.15 | 93,864 | |
| Dube Michael P | NTLA | VP, Chief Accounting Officer | Jan 5, 2026 | Sell | $9.21 | 2,989 | $27,528.69 | 52,277 | |
| Schultes Birgit C | NTLA | EVP, Chief Scientific Officer | Jan 5, 2026 | Sell | $9.21 | 8,508 | $78,358.68 | 98,533 |
Earnings Transcripts
SEC 8-K filings with transcript text
2025 Q4 Q4 2025 Earnings
8-K SELL Feb 26, 2026 · 100% conf.
Q4 2025 Earnings
8-K SELLFeb 26, 2026 · 100% conf.
1D
-5.77%
$13.46
Act: -4.62%
5D
-9.82%
$12.88
Act: -7.91%
20D
-9.34%
$12.95
8-K
false000165213000016521302026-02-262026-02-26
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): February 26, 2026
INTELLIA THERAPEUTICS, INC.
(Exact name of Registrant as Specified in Its Charter)
Delaware
001-37766
36-4785571
(State or Other Jurisdiction of Incorporation)
(Commission File Number)
(IRS Employer Identification No.)
40 Erie Street, Suite 130
Cambridge, Massachusetts
02139
(Address of Principal Executive Offices)
(Zip Code)
Registrant’s Telephone Number, Including Area Code: 857 285-6200
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, par value $0.0001 per share
NTLA
The Nasdaq Global Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition. On February 26, 2026, Intellia Therapeutics, Inc. announced its financial results and business updates for the quarter and year ended December 31, 2025. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 on this Current Report on Form 8-K. The information in this report furnished pursuant to Item 2.02 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section. It may only be incorporated by reference in another filing under the Exchange Act or the Securities Act of 1933, as amended, if such subsequent filing specifically references the information furnished pursuant to Item 2.02 of this report. Item 9.01 Financial Statements and Exhibits. (d) Exhibits
Exhibit No.
Description
99.1
Press release dated February 26, 2026.
104
Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
Intellia Therapeutics, Inc.
Date:
February 26, 2026
By:
/s/ John M. Leonard
Name: John M. Leonard Title: Chief Executive Officer and President
2025 Q3 Q3 2025 Earnings
8-K Nov 6, 2025
Q3 2025 Earnings
8-KNov 6, 2025
8-K
false 0001652130 0001652130 2025-11-06 2025-11-06
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 06, 2025
INTELLIA THERAPEUTICS, INC.
(Exact name of Registrant as Specified in Its Charter)
Delaware
001-37766
36-4785571
(State or Other Jurisdiction of Incorporation)
(Commission File Number)
(IRS Employer Identification No.)
40 Erie Street, Suite 130
Cambridge, Massachusetts
02139
(Address of Principal Executive Offices)
(Zip Code) Registrant’s Telephone Number, Including Area Code: 857 285-6200 Not Applicable (Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, par value $0.0001 per share
NTLA
The Nasdaq Global Market Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition. On November 6, 2025, Intellia Therapeutics, Inc. announced its financial results and business updates for the quarter ended September 30, 2025. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 on this Current Report on Form 8-K. The information in this report furnished pursuant to Item 2.02 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section. It may only be incorporated by reference in another filing under the Exchange Act or the Securities Act of 1933, as amended, if such subsequent filing specifically references the information furnished pursuant to Item 2.02 of this report. Item 9.01 Financial Statements and Exhibits. (d) Exhibits
Exhibit No.
Description
99.1
Press release dated November 6, 2025.
104
Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
Intellia Therapeutics, Inc.
Date: November 6, 2025
By:
/s/ John M. Leonard
Name: John M. Leonard Title: Chief Executive Officer and President
2025 Q2 Q2 2025 Earnings
8-K Aug 7, 2025
Q2 2025 Earnings
8-KAug 7, 2025
8-K
0001652130false00016521302025-08-072025-08-07
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): August 07, 2025
INTELLIA THERAPEUTICS, INC.
(Exact name of Registrant as Specified in Its Charter)
Delaware
001-37766
36-4785571
(State or Other Jurisdiction of Incorporation)
(Commission File Number)
(IRS Employer Identification No.)
40 Erie Street, Suite 130
Cambridge, Massachusetts
02139
(Address of Principal Executive Offices)
(Zip Code)
Registrant’s Telephone Number, Including Area Code: 857 285-6200
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, par value $0.0001 per share
NTLA
The Nasdaq Global Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition. On August 7, 2025, Intellia Therapeutics, Inc. announced its financial results and business updates for the quarter ended June 30, 2025. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 on this Current Report on Form 8-K. The information in this report furnished pursuant to Item 2.02 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section. It may only be incorporated by reference in another filing under the Exchange Act or the Securities Act of 1933, as amended, if such subsequent filing specifically references the information furnished pursuant to Item 2.02 of this report. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On August 7, 2025, the Company announced that Dr. David Lebwohl, M.D., the Company’s Executive Vice President and Chief Medical Officer (“CMO”), will retire from the Company, effective August 7, 2026. Upon his retirement, Dr. Lebwohl will be eligible for the equity treatment set forth in the Company’s Amended and Restated Retirement Policy for Equity Awards (the “Retirement Policy”), a copy of which was filed as Exhibit 10.30 to the Company’s Annual Report on Form 10-K (File No. 001-37766) filed with the Securities and Exchange Commission on February 23, 2023. Dr. Lebwohl will continue to serve as the Company’s Executive Vice President and CMO until a successor is appointed and will continue to be employed by the Company until his retirement. Item 9.01 Financial Statements and Exhibits. (d) Exhibits
Exhibit No.
Description
99.1
Press release dated August 7, 2025.
104
Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
Intellia Therapeutics, Inc.
Date:
August 7, 2025
By:
/s/ John M. Leonard
Name: John M. Leonard Title: Chief Executive Officer and President
Compare NTLA vs Leading Stocks
See how NTLA stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "NTLA Intellia Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.